136 related articles for article (PubMed ID: 7518983)
21. Correlations between parameters in pressure-flow analysis and histological compositions in prostate in patients with benign prostatic hyperplasia.
Ichiyanagi O; Nakada T
Urol Int; 1997; 59(3):154-60. PubMed ID: 9428431
[TBL] [Abstract][Full Text] [Related]
22. Relation between urethral elasticity and bladder outlet obstruction and histologic composition of the prostate in patients with benign prostatic hyperplasia.
Ichiyanagi O; Sasagawa I; Suzuki Y; Ishigooka M; Nakada T
Urology; 1999 Jun; 53(6):1149-53. PubMed ID: 10367844
[TBL] [Abstract][Full Text] [Related]
23. Limitations of transition zone needle biopsy findings in the prediction of transition zone cancer and tissue composition of benign nodular hyperplasia.
McNeal J; Noldus J
Urology; 1996 Nov; 48(5):751-6. PubMed ID: 8911519
[TBL] [Abstract][Full Text] [Related]
24. Correlation between morphometric differences and norepinephrine content in benign prostatic hyperplasia.
Ishigooka M; Hashimoto T; Hayami S; Suzuki Y; Sasagawa I; Nakada T
Prostate; 1996 Jun; 28(6):385-91. PubMed ID: 8650076
[TBL] [Abstract][Full Text] [Related]
25. Cytoskeletal and cytocontractile protein composition of stromal tissue in normal, hyperplastic, and neoplastic human prostate. An immunocytochemical study with monoclonal antibodies.
Castellucci E; Prayer-Galetti T; Roelofs M; Pampinella F; Faggian L; Gardiman M; Pagano F; Sartore S
Ann N Y Acad Sci; 1996 Apr; 784():496-508. PubMed ID: 8651605
[TBL] [Abstract][Full Text] [Related]
26. [Is a single prostatic biopsy sufficient for selection of medical treatment in benign prostatic hypertrophy?].
Zlotta AR; Sattar AA; Wespes E; Haot J; Schulman CC
Acta Urol Belg; 1995 Mar; 63(1):83-7. PubMed ID: 7537013
[TBL] [Abstract][Full Text] [Related]
27. Functional property, norepinephrine content and morphometric findings in human hyperplastic prostate.
Ishigooka M; Hashimoto T; Suzuki Y; Ichiyanagi O; Sasagawa I; Aoyama N; Nakada T
Prostate; 1997 Nov; 33(3):183-7. PubMed ID: 9365546
[TBL] [Abstract][Full Text] [Related]
28. [Changes in prostatic stromal composition and benign prostatic hyperplasia].
Shen W; Mao XM; Lü J; Yao HQ; Deng ZX; Zhao YB; Liu J; Hua W; Wang BQ; Hu WL
Zhonghua Nan Ke Xue; 2011 Aug; 17(8):703-6. PubMed ID: 21898992
[TBL] [Abstract][Full Text] [Related]
29. Age-related changes of histological composition in established benign prostatic hyperplasia.
Ishigooka M; Hayami S; Suzuki Y; Hashimoto T; Sasagawa I; Nakada T
Eur Urol; 1996; 29(1):85-9. PubMed ID: 8821697
[TBL] [Abstract][Full Text] [Related]
30. Histologic differences in benign prostate hyperplasia between Chinese and American men.
Yu EY; Siegal JA; Meyer GE; Ji XR; Ni XZ; Brawer MK
Prostate; 1997 May; 31(3):175-9. PubMed ID: 9167769
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams).
Tan AH; Gilling PJ; Kennett KM; Frampton C; Westenberg AM; Fraundorfer MR
J Urol; 2003 Oct; 170(4 Pt 1):1270-4. PubMed ID: 14501739
[TBL] [Abstract][Full Text] [Related]
32. Prostatic epithelial and luminal area in the transition zone acini: morphometric analysis in normal and hyperplastic human prostate.
Babinski MA; Chagas MA; Costa WS; Sampaio FJ
BJU Int; 2003 Oct; 92(6):592-6. PubMed ID: 14511041
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of NKX3.1 in benign prostatic hyperplasia.
Irer B; Toylu A; Aslan G; Celebi I; Yorukoglu K; Atabey N
Urology; 2009 May; 73(5):1140-4. PubMed ID: 18597829
[TBL] [Abstract][Full Text] [Related]
34. Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia.
Cadeddu JA; Pearson JD; Lee BR; Landis P; Partin AW; Epstein JI; Carter HB
Urology; 1995 May; 45(5):795-800. PubMed ID: 7538241
[TBL] [Abstract][Full Text] [Related]
35. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
Yang XJ; Lecksell K; Short K; Gottesman J; Peterson L; Bannow J; Schellhammer PF; Fitch WP; Hodge GB; Parra R; Rouse S; Waldstreicher J; Epstein JI
Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
[TBL] [Abstract][Full Text] [Related]
36. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of histological structure and its effect on the distribution of alpha1-adrenoceptors in human benign prostatic hyperplasia.
Kurimoto S; Moriyama N; Hamada K; Kawabe K
Br J Urol; 1998 Mar; 81(3):388-93. PubMed ID: 9523657
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH).
Elshal AM; Elmansy HM; Elhilali MM
BJU Int; 2012 Dec; 110(11 Pt C):E845-50. PubMed ID: 22702908
[TBL] [Abstract][Full Text] [Related]
39. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.
Ornstein DK; Rao GS; Smith DS; Andriole GL
J Urol; 1997 Mar; 157(3):880-3; discussion 883-4. PubMed ID: 9072591
[TBL] [Abstract][Full Text] [Related]
40. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
